TET2 and B-cell non-Hodgkin lymphoma: Here, we elaborate a summary of TET2 mutations in the frequent co-occurrence of AITL and B-cell lymphomas (e.g., diffuse large B-cell lymphoma and classic Hodgkin lymphoma) and discuss the potential of targeting TET2 as an anti-AITL agent.